drug
ORIAHNN (COPACKAGED)
Marketedupdated 5mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- tagApproval20 co-mentions · 5 sources
- drugelagolix sodium + estradiol + norethindrone + elagolix sodium10 co-mentions · 5 sources
- drugelagolix sodium10 co-mentions · 5 sources
- drugESTRING10 co-mentions · 5 sources
- drugORILISSA10 co-mentions · 5 sources
- drugnorethindrone10 co-mentions · 5 sources
- tagSmall Molecule10 co-mentions · 5 sources
all catalysts(5)
approval · 5
May 29, 2020
approval
$ABBV263.29-1.12%
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Aug 2, 2021
approval
$ABBV263.29-1.12%
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Jun 5, 2023
approval
$ABBV263.29-1.12%
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Jul 30, 2024
approval
$ABBV263.29-1.12%
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Dec 17, 2025
approval
$ABBV263.29-1.12%
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 7, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Aug 27, 2040method-of-use (U-3655)US 11690845
- Jul 23, 2039compositionUS 11542239
- Aug 20, 2038formulationUS 12083227
- Mar 14, 2034method-of-use (U-2842)US 10881659
- Mar 14, 2034method-of-use (U-2842)US 11045470
- Jul 6, 2029compositionUS 74199832.8y
- Nov 7, 2028formulationUS 114593052.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that